Drug
Optimized Treatment (OPT)
Optimized Treatment (OPT) is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution1 total trials
Phase 4Post-market surveillance
1(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 41 (100.0%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completed
the Long-term Retention Rate and Influence Factors of Individualized Treatment of Vedolizumab in Ulcerative Colitis
NCT06856031
completed
The Clinical Efficacy and Influence Factors of Individualized Treatment of Ustekinumab in Crohn's Disease
NCT06785493
completedphase_4
Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder
NCT00667745
Clinical Trials (3)
Showing 3 of 3 trials
NCT06856031
the Long-term Retention Rate and Influence Factors of Individualized Treatment of Vedolizumab in Ulcerative Colitis
NCT06785493
The Clinical Efficacy and Influence Factors of Individualized Treatment of Ustekinumab in Crohn's Disease
NCT00667745Phase 4
Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3